Completed PHASE1 INTERVENTIONAL 4-arm NCT01088711

Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes

Sponsor: Merck Sharp & Dohme LLC

Conditions Type 2 Diabetes (T2D)

Interventions Omarigliptin Placebo

Updated 11 times since 2017 Last updated: Aug 8, 2018 Started: Mar 11, 2010 Primary completion: May 11, 2010 Completion: May 11, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01088711, this PHASE1 trial focuses on Type 2 Diabetes (T2D) and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 11 times since 2010, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jun 2022 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 6 earlier versions

Jan 2021 — Jun 2022 [monthly]

Completed PHASE1
Oct 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Oct 2018 [monthly]

Completed PHASE1
Aug 2017 — Jun 2018 [monthly]

Completed PHASE1
Feb 2017 — Aug 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.